Abstract：
OBJECTIVE: This study aimed to systematically evaluate the clinical efficacy of gabapentin and pregabalin in the treatment of acute herpes zoster (HZ) neuralgia, including pain control and the occurrence of adverse effects.
METHODS: A systematic computerized search was conducted in October 2023 in PubMed, Embase, Web of Science, Cochrane Library, VIP, CNKI, and Wanfang databases. Data from randomized controlled trials (RCTs) comparing gabapentin analogs for the treatment of acute HZ neuralgia were searched. Endpoints were visual analog scores (Visual Analog Scale) and adverse effects at 1, 2, and 4 weeks. Data from studies that met the inclusion criteria were extracted for meta-analysis and sensitivity analysis using Revman 5.4 and Stata16.
RESULTS: The study included 292 patients from 6 RCTs. Of these, 118 were in the gabapentin-treated group, 37 were in the pregabalin-treated group, and 137 were in the placebo-controlled group. The gabapentin group showed superior pain reduction compared with the placebo group ( P < 0.05), but adverse events were more frequent.
CONCLUSIONS: Gabapentin can effectively reduce acute HZ neuralgia in patients. Pregabalin requires additional RCTs to supplement the analysis.
METHODS: A systematic computerized search was conducted in October 2023 in PubMed, Embase, Web of Science, Cochrane Library, VIP, CNKI, and Wanfang databases. Data from randomized controlled trials (RCTs) comparing gabapentin analogs for the treatment of acute HZ neuralgia were searched. Endpoints were visual analog scores (Visual Analog Scale) and adverse effects at 1, 2, and 4 weeks. Data from studies that met the inclusion criteria were extracted for meta-analysis and sensitivity analysis using Revman 5.4 and Stata16.
RESULTS: The study included 292 patients from 6 RCTs. Of these, 118 were in the gabapentin-treated group, 37 were in the pregabalin-treated group, and 137 were in the placebo-controlled group. The gabapentin group showed superior pain reduction compared with the placebo group ( P < 0.05), but adverse events were more frequent.
CONCLUSIONS: Gabapentin can effectively reduce acute HZ neuralgia in patients. Pregabalin requires additional RCTs to supplement the analysis.
摘要：
目的：他的研究旨在系统评价加巴喷丁和普瑞巴林治疗急性带状疱疹神经痛的临床疗效。包括疼痛控制和不良反应的发生。
方法：2023年10月在PubMed进行了系统的计算机化搜索，Embase,WebofScience,科克伦图书馆,VIP,CNKI,和万方数据库。检索了比较加巴喷丁类似物治疗急性带状疱疹神经痛的随机对照试验的数据。终点为视觉模拟评分(VAS)和第1、2和4周的不良反应。使用Revman5.4和Stata16提取符合纳入标准的研究数据进行荟萃分析和敏感性分析。
结果：该研究包括来自6个随机对照试验的292名患者。其中,118人在加巴喷丁治疗组中，37人在普瑞巴林治疗组中，安慰剂对照组137例.加巴喷丁组疼痛减轻优于安慰剂组(P<0.05),但不良事件更常见.
结论：加巴喷丁可有效减轻患者急性带状疱疹神经痛。普瑞巴林需要额外的随机对照试验来补充分析。
■CRD42023446643。
方法：2023年10月在PubMed进行了系统的计算机化搜索，Embase,WebofScience,科克伦图书馆,VIP,CNKI,和万方数据库。检索了比较加巴喷丁类似物治疗急性带状疱疹神经痛的随机对照试验的数据。终点为视觉模拟评分(VAS)和第1、2和4周的不良反应。使用Revman5.4和Stata16提取符合纳入标准的研究数据进行荟萃分析和敏感性分析。
结果：该研究包括来自6个随机对照试验的292名患者。其中,118人在加巴喷丁治疗组中，37人在普瑞巴林治疗组中，安慰剂对照组137例.加巴喷丁组疼痛减轻优于安慰剂组(P<0.05),但不良事件更常见.
结论：加巴喷丁可有效减轻患者急性带状疱疹神经痛。普瑞巴林需要额外的随机对照试验来补充分析。
■CRD42023446643。
